APOA5 and metabolic dysfunction-associated steatotic liver disease: An investigation led by Sharma et al reported that injection of hApoA5 into ApoA5 knockout mice indeed significantly reduced plasma TG levels on chow diet, but unfortunately, there was no change in the hepatic TG contents between null-AAV and hApoA5-AAV groups 17, which suggested that targeting ApoA5 in other animal species should be considered to better understand the relationship between ApoA5 deficiency and NAFLD.